Panbela Therapeutics, Inc. (PBLA)

Panbela Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cost of Revenue	27.5	25.65	35.73	10.01	5.75	4.32
Gross Profit	-27.5	-25.65	-35.73	-10.01	-5.75	-4.32
Selling, General & Admin	4.89	5.03	6.04	4.59	3.25	1.97
Research & Development	22.61	20.61	28.05	5.42	2.51	2.35
Other Operating Expenses	-0.32	0	-0.68	-0.6	0.61	-0.1
Operating Expenses	27.49	25.65	34.09	10.01	5.75	4.32
Operating Income	-35.34	-51.29	-34.09	-10.01	-5.75	-4.32
Interest Income	0.11	0.12	0.01	0	0	0
Interest Expense	0.13	-0.32	0.29	0.01	0.02	2.19
Other Expense / Income	-7.79	-25.41	0.68	0.6	-0.71	0.1
Pretax Income	-27.58	-25.45	-35.05	-10.62	-5.06	-6.62
Income Tax	-0.32	-0.19	-0.12	-0.49	-0.3	-0.42
Net Income	-27.26	-25.26	-34.93	-10.14	-4.77	-6.2
Shares Outstanding (Basic)	3	0	0	0	0	0
Shares Outstanding (Diluted)	3	0	0	0	0	0
Shares Change	23880.32%	-87.32%	75.72%	51.42%	35.66%	-93.89%
EPS (Basic)	-215.14	-232429.55	-40748.57	-20773.70	-14798.10	-26103.83
EPS (Diluted)	-215.14	-232429.55	-40748.57	-20773.70	-14798.10	-26103.83
Free Cash Flow	-24.89	-25.25	-15.94	-6.7	-3.85	-2.74
Free Cash Flow Per Share	-7.96	-232300.74	-18588.99	-13741.18	-11961.39	-11532.00
EBITDA	-35.22	-51.29	-34.76	-10.61	-5.15	-4.42
Depreciation & Amortization	0	0	0	0	0.11	2.07
EBIT	-	-	-	-	-5.26	-6.49

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.